Literature DB >> 28366633

Wnt signaling promotes androgen-independent prostate cancer cell proliferation through up-regulation of the hippo pathway effector YAP.

Won Ik Seo1, Seoyoung Park2, Jungsug Gwak3, Bong Gun Ju3, Jae Il Chung1, Pil Moon Kang4, Sangtaek Oh5.   

Abstract

Aberrant up-regulation of Wnt/β-catenin signaling is associated with the development and progression of prostate cancer, but the underlying mechanism is unclear. Here we show that in the absence of androgens, the Wnt/β-catenin pathway activates AR-mediated transcription through up-regulation of the Hippo pathway effector Yes-associated protein (YAP). Wnt3a-conditioned medium (Wnt3a-CM) promotes the growth of LNCaP cells and increases AR and YAP protein levels. Moreover, Wnt3a-CM induces the nuclear translocation of YAP and the AR, but not β-catenin, thereby activating the expression of AR- and YAP-dependent genes, in an androgen-independent manner. In addition, depletion of YAP with small interfering RNA (siRNA) prevented Wnt3a-CM-mediated up-regulation of AR-dependent gene expression. Thus, our findings provide mechanistic insight into the proposed cross-talk between the Wnt/β-catenin and Hippo pathways in androgen-independent prostate cancer development.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Androgen receptor (AR); Hippo signaling; Prostate cancer; Wnt/β-catenin signaling; Yes-associated protein (YAP)

Mesh:

Substances:

Year:  2017        PMID: 28366633     DOI: 10.1016/j.bbrc.2017.03.158

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

1.  SCC-S2 Facilitates Tumor Proliferation and Invasion via Activating Wnt Signaling and Depressing Hippo Signaling in Colorectal Cancer Cells and Predicts Poor Prognosis of Patients.

Authors:  Chuanjia Yang; Weixue Xu; Xiangzhen Meng; Siqi Zhou; Minglu Zhang; Dongxu Cui
Journal:  J Histochem Cytochem       Date:  2018-09-14       Impact factor: 2.479

2.  Identification and differentiation therapy strategy of pterygium in vitro.

Authors:  Xinyuan Hu; Nitin Tandra; Zhijian Zhang; Aihua Gong; Jingyan Chen; Yang Li; Qian Chen; Wenrong Xu; Hui Qian
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 3.  Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.

Authors:  Ju-Won Jang; Min-Kyu Kim; Suk-Chul Bae
Journal:  Small GTPases       Date:  2018-04-20

Review 4.  Dual roles of yes-associated protein (YAP) in colorectal cancer.

Authors:  Chunlin Ou; Zhenqiang Sun; Shen Li; Guiyuan Li; Xiayu Li; Jian Ma
Journal:  Oncotarget       Date:  2017-08-11

5.  URG11 Regulates Prostate Cancer Cell Proliferation, Migration, and Invasion.

Authors:  Bin Pan; Yunlin Ye; Haiping Liu; Jianli Zhen; Hongmei Zhou; Yutong Li; Lijun Qu; Youke Wu; Chuanrong Zeng; Weifeng Zhong
Journal:  Biomed Res Int       Date:  2018-05-31       Impact factor: 3.411

6.  Profiling and bioinformatics analyses of differential circular RNA expression in prostate cancer cells.

Authors:  Chunlei Zhang; Jun Xiong; Qi Yang; Ye Wang; Haoqing Shi; Qinqin Tian; Hai Huang; Depei Kong; Jianmin Lv; Dan Liu; Xu Gao; Xiaoyuan Zi; Yinghao Sun
Journal:  Future Sci OA       Date:  2018-10-03

7.  miR-193b regulates tumorigenesis in liposarcoma cells via PDGFR, TGFβ, and Wnt signaling.

Authors:  Ying Z Mazzu; Yulan Hu; Yawei Shen; Thomas Tuschl; Samuel Singer
Journal:  Sci Rep       Date:  2019-03-01       Impact factor: 4.379

Review 8.  Dysregulated Transcriptional Control in Prostate Cancer.

Authors:  Simon J Baumgart; Ekaterina Nevedomskaya; Bernard Haendler
Journal:  Int J Mol Sci       Date:  2019-06-13       Impact factor: 5.923

Review 9.  The Hippo Pathway in Prostate Cancer.

Authors:  Omar Salem; Carsten G Hansen
Journal:  Cells       Date:  2019-04-23       Impact factor: 6.600

10.  miR‑590‑5p inhibits tumor growth in malignant melanoma by suppressing YAP1 expression.

Authors:  Kuanhou Mou; Meiling Ding; Dan Han; Yan Zhou; Xin Mu; Wenli Liu; Lijuan Wang
Journal:  Oncol Rep       Date:  2018-08-07       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.